References
- Barlogie B., Alexanian R., Jagannath S. Plasma cell dyscrasias. JAMA 1992; 268: 2946–2951
- Alexanian R., Fraschini G., Smith L. Amyloidosis in multiple myeloma with or without apparent cause. Arch Intern Med 1984; 144: 2158–2160
- Kyle R.A. Multiple myeloma review of 869 cases. Mayo Clin Proc 1975; 50: 29–40
- Pruzanski W., Katz A. Clinical and laboratory findings in primary generalized and multiple myeloma related amyloidosis. CMA journal 1976; 114: 906–909
- Ameis A., Ko H.S., Pruzanski W. M components- A review of 1242 cases. CMA journal 1976; 114: 889–893
- Fielder K., Durie B.G.M. Primary amyloidosis associated with multiple myeloma: Predictors of successful therapy. Am J Med 1986; 80: 413–418
- Kyle R.A., Greipp P.R. Amyloidosis (AL) clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665–683
- Gertz M., Li C.Y., Shirahama T., Kyle R.A. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain). Arch Int Med 1988; 148: 929–933
- Kyle R.A., Greipp P.R., O'fallon M. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. 1986; 68: 220–224
- Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.R., Cassassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. NEJM 1996; 335: 91–97
- Barlogie B., Jagannath S., Vesole D., Naucke S., Cheson B., Mattox S., Bracy D., Salmon S., Jacobson J., Crowley J., Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793
- Ivanyi B. Frequency of light chain deposition nephropathy in relation to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990; 114: 986–987
- Kapadia S.B. A clinicopathological study of 62 consecutively autopsied cases. Medicine 1980; 59: 380–392
- Solomon A., Weiss D.T., Kattine A.A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324: 1845–1848
- Dhodapkar M., Merlini P., Solomon A. Immunoglobulin deposition diseases and primary systemic (AL) amyloidosis; Biology and therapy. Clinics of Hematology/Oncology of North America 1997, (in press)
- Comenzo R.L., Vosburgh E., Simms R.W., Bergethon P., Sarnacki D., Finn K., Dubrey S., Faller D.V., Wright D.G., Falk R.H., Skinner M. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis; one-year follow-up in five patients. Blood 1996; 88: 2801–2806
- Vanburen M., Hene R.J., Verdnok L.F., Verzijlbergen F.J., Lockhorst H.M. Clinical remission after syngeneic transplantation in a patient with AL amyloidosis. Ann. Int. Med. 1995; 122: 508–510
- Tricot G., Sawyer J., Jagannath S. Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256
- Vesole D.H., Tricot G., Jagannath S. Auto-transplants in multiple myeloma; what have we learned. Blood 1996; 88: 838–847